Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mismatch Repair01:20

Mismatch Repair

7.1K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.1K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.9K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.

Cell death discovery·2022
Same author

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

HemaSphere·2022
Same author

MYC multimers shield stalled replication forks from RNA polymerase.

Nature·2022
Same author

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Cancers·2022
Same author

Vitamin D Receptor Expression Is Significantly Decreased in Bone Metastases Compared to Matched Primary Breast Cancer Tumours.

Cancer investigation·2022
Same author

Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.

Cancers·2022

関連する実験動画

Updated: Apr 13, 2026

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
10:39

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection

Published on: November 27, 2014

8.6K

ヒトリンパ腫における腫瘍学的活性MYD88変異.

Vu N Ngo1, Ryan M Young, Roland Schmitz

  • 1Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Nature
|December 24, 2010
PubMed
まとめ

活性化されたB細胞型のDLBCLの生存率は,MYD88アダプタータンパク質の変異に依存しています. これらの腫瘍性MYD88変異,特にL265Pは,重要なシグナル伝達経路を活性化することによって,リンパ腫細胞の成長を駆動し,新しい治療標的を提供します.

さらに関連する動画

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

2.0K

関連する実験動画

Last Updated: Apr 13, 2026

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
10:39

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection

Published on: November 27, 2014

8.6K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

2.0K

科学分野:

  • 腫瘍学 腫瘍学
  • 分子生物学は分子生物学である.
  • 免疫学 免疫学とは

背景:

  • 活性化されたB細胞型 (ABC) 拡散型大B細胞リンパ腫 (DLBCL) は,治療の選択肢が限られている挑戦的なサブタイプです.
  • 構成核因子 (NF) -κBとJAKキナーゼのシグナル伝達経路は,ABC DLBCL細胞の生存に不可欠です.
  • この異常なシグナリングの正確な遺伝的基盤は,まだ完全に理解されていません.

研究 の 目的:

  • ABC DLBCLの病原性におけるMYD88アダプタータンパク質の役割を調査する.
  • ABC DLBCL腫瘍内のMYD88の腫瘍性変異を特定し,特徴づけること.
  • 信号伝達経路と細胞生存に対するMYD88変異の機能的影響を明らかにする.

主な方法:

  • MYD88,IRAK1,IRAK4がABC DLBCL生存に不可欠であるかどうかを評価するためのRNA干渉スクリーニング.
  • MYD88.8.の突然変異を特定するために,高通量RNA再配列解析を行います.
  • MYD88変異がタンパク質複合体の組立,キナーゼ活性,および下流信号伝達に及ぼす影響を評価するための機能分析.

主要な成果:

  • MYD88および関連するキナーゼIRAK1/IRAK4は,ABC DLBCL細胞生存に不可欠である.
  • MYD88 Toll/IL-1受容体 (TIR) ドメインの再発性腫瘍原性変異は,ABC DLBCLで確認されました.
  • MYD88におけるL265P置換は,ABC DLBCL腫瘍の29%で発見され,機能獲得変異として作用し,構成信号伝達と細胞生存を促進します.
  • MYD88変異は,粘膜関連リンパ性組織リンパ腫を含む他のリンパ腫サブタイプでも観察されました.

結論:

  • MYD88シグナル伝達経路は,ABC DLBCLの病原化に不可欠である.
  • L265Pのような機能獲得型MYD88変異は,NF-κBとJAK/STAT3経路を活性化することによって腫瘍発生を誘発する.
  • IRAK4キナーゼとMYD88経路の他のコンポーネントをターゲットにすることは,MYD88変異のDLBCLに対する有望な治療戦略です.